SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (372)9/30/1998 12:45:00 PM
From: mauser96   of 717
 
I like the implications of the phase III Gd-Tex trials. It shouldn't be too hard to get trial participants since the prognosis is so bleak, and it has a clear end point. Also, at the 2/3 point if it appears to be working the controls will be switched to the drug. This is one trial that won't drag on for 5 or 6 years, and even the FDA can't argue whether people are alive or dead. Even if a drug is approved ,it is often a very slow process to get cost sensitive managed care providers to use it. If a significant increased survival time is shown HMO's will be forced to use the drug.
However, it's still a gamble and even if the trials turn out well profits are years away. I am dubious about TA in stocks like this, but there is some support near today's price, and we are off 50% from the highs.
BTW, the news concerning the trial isn't showing up on my Charles Schwab "News Headlines" report.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News